Search

everythinglearnresearchcommunity

for

Search:↓

The conversation discusses a patent for using topical resveratrol and melatonin to treat androgenetic alopecia (AGA) and also mentions interest in topical sulforaphane as a treatment.

The conversation discusses creating a personalized topical treatment for hair loss, with ingredients like finasteride, minoxidil, tretinoin, melatonin, caffeine, and others. Users share their ideal formulations, including combinations of minoxidil, finasteride, tretinoin, adenosine, and other compounds, while also discussing the importance of managing inflammation.

GT20029 is a potential treatment for androgenetic alopecia, addressing the root cause by targeting androgen receptors, unlike Minoxidil or Finasteride. It is seen as a preventative measure rather than a regrowth agent, with hopes for market release soon.

The side effects of taking finasteride as a treatment for hair loss, with particular focus on its sexual and psychiatric side effects; research has indicated that there are high and low outliers in terms of prevalence of sexual side effects, but it is usually between 3-5%, while evidence of lasting sexual side effects comes from lower quality sources.

The user noticed improvement in skin tags after using oral and topical finasteride and minoxidil, along with other supplements like thiamine, P5P, serrapeptase, nattokinase, and retinol. They are unsure which treatment caused the improvement and are seeking input on whether finasteride's DHT reduction could be responsible.

Topical finasteride results in plasma levels 100 times lower than oral finasteride, potentially reducing systemic side effects. Users report similar efficacy with fewer side effects, suggesting a preference for topical application.

Body hair is more resilient than scalp hair due to different gene expressions and DHT sensitivity. Treatments like minoxidil and finasteride are used for hair loss, but they have varying effects on body and scalp hair.

PP405 is a potential hair loss treatment undergoing trials, with discussions on its effectiveness and comparison to existing treatments like finasteride and minoxidil. There is skepticism about its status as a cure, with hopes for future advancements in genetic treatments like CRISPR.

Verteporfin and FAK inhibitors being looked at as potential treatments for hair regeneration, with updates on the unofficial off-label human trial being discussed.

New hair loss treatments like Shiseido/Replicel and Histogen were discussed, with cautious optimism about their availability by 2018. Setipiprant, Replicel, and Bimatoprost were mentioned as potential treatments expected around 2016-2017.

The conversation discusses GT20029 as a potential cure for hair loss and includes information on specific treatments used. Minoxidil, finasteride, and RU58841 are mentioned as related treatments.

The conversation discusses the effectiveness of reducing DHT for hair loss treatment and explores alternative approaches like reducing androgen receptor sensitivity. Specific treatments mentioned include finasteride, dutasteride, pyrilutamide (KX-826), GT20029, and RU58841.

Best 2% Minox brand for mixing with pyrilutamide powder and retinoic acid sought. Advice on specific treatments discussed.

Analyzing data on pyrilutamide, a potential hair loss treatment, as well as the effectiveness of other treatments such as Minoxidil, Finasteride, and RU58841.

Common misconceptions about hair loss treatments include the belief that lower doses of finasteride are as effective as higher doses, and that ketoconazole is effective for androgenetic alopecia without scalp issues. Additionally, minoxidil's effects can be seen sooner than commonly thought, and topical dutasteride is effective.

Estrogen injections significantly improved hair growth, particularly on the crown, after stopping finasteride. Monotherapy with estrogen led to hairline improvement, but also caused sterility and potential feminization effects.

The conversation is about optimism for new hair loss treatments like Stemson's bioengineering, osteopotin, SCUBE3, GT20029, and Verteprofin, and inquires about other notable treatments.

The user is concerned about hair loss despite taking finasteride and has a hair transplant scheduled. They experience scalp itching and burning, which hasn't been relieved by various treatments, and another user suggests using ghk-cu & ahk-cu serum and Koshine kx-826/pyrilutamide for relief.

The conversation discusses hair loss treatments, specifically Regenera stem cells and exosomes from 'Cellgenic' umbilical cord donors. The user has been using topical minoxidil 5% and 0.001% estradiol for a year without seeing effects, and another user mentions the importance of microneedling.

The post discusses a theory that hair regrowth after transplant is due to the angiogenesis process (new blood vessels forming), not because the transplanted hair is unaffected by DHT. The responses highlight the established belief in 'donor dominance' (the importance of the hair's origin in transplantation) and skepticism about the new theory.

A user shared their hair loss journey, starting treatments with topical minoxidil and finasteride at 17, and later adding oral versions and dutasteride by age 20, but still experiencing hair loss. Others suggested that the treatments have likely slowed the progression, and some recommended considering a hair transplant or adjusting medication, while expressing concerns about the potential side effects of starting such treatments at a young age.

Phase II for TDM-105795 for Androgenic Alopecia is set to begin in April 2023. The study aims to evaluate the efficacy and safety of TDM-105795 in male subjects.

KX-826 (Pyrilutamide) being tested in the US for hair loss treatment and that they have found enough people to participate in phase II clinical trials. Other treatments discussed are Minoxidil, finasteride, and RU58841.

The conversation discusses switching from oral to topical treatments for hair loss, specifically using a mix of retinoic acid, finasteride, and minoxidil, after oral treatments like dutasteride and finasteride were ineffective. The user is concerned about the cost and potential impact of dandruff on the absorption of topical treatments.

Dutasteride and finasteride have similar risks of sexual dysfunction for treating androgenetic alopecia. Users experience varying side effects, indicating individual differences in drug reactions.

KX-826 hair loss treatment completed trials with mild side effects. GT20029 may be ultimate cure, destroying androgen receptors causing baldness.

Attempting to treat hair loss with Finasteride, and other treatments such as Minoxidil, RU58841, and DUT were suggested.

The user has been using a combination of finasteride/dutasteride, minoxidil, tretinoin, and hydrocortisone with microneedling and ketoconazole shampoo for hair loss. They are asking if the baby hairs growing will turn into terminal hairs with continued treatment.

The conversation discusses the effectiveness of topical tretinoin as a monotherapy for hair loss, with users suggesting it may not be as effective as minoxidil or finasteride. The original poster is considering other options like a phenol peel and is concerned about the risks of derma rolling.

A user shared their experience with hair loss treatments, including finasteride, minoxidil, and RU58841, which improved their hair from a diffuse NW3 to a solid NW2 - 2.5. They noticed significant changes in how people treated them after regrowing their hair, suggesting that attractiveness can greatly impact social interactions and opportunities.